XML 47 R36.htm IDEA: XBRL DOCUMENT v3.25.2
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2025
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Summary of Stock Based Compensation for Employees and Non Employees

Under each of the legal entity’s equity plans, we recorded stock-based compensation in the following expense categories on our condensed consolidated statements of operations for employees and non-employees:

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

 

(in thousands)

 

Cost of goods sold

 

$

126

 

 

$

—

 

 

$

217

 

 

$

—

 

Research and development

 

 

14,000

 

 

 

4,937

 

 

 

25,255

 

 

 

17,716

 

Selling, general and administrative

 

 

23,213

 

 

 

16,471

 

 

 

41,211

 

 

 

32,542

 

Restructuring, impairment and related charges

 

 

—

 

 

 

43

 

 

 

46

 

 

 

43

 

Total stock-based compensation

 

$

37,339

 

 

$

21,451

 

 

$

66,729

 

 

$

50,301

 

 
Summary of Stock Option Activity

The following table summarizes BridgeBio’s stock option activity under the Plans for the six months ended June 30, 2025:

 

 

 

Options
Outstanding

 

 

Weighted-Average
Exercise Price
per Option

 

 

Weighted-Average
Remaining
Contractual
Life (years)

 

 

Aggregate
Intrinsic
Value
(in thousands)

 

Outstanding as of December 31, 2024

 

 

 

 

 

12,499,883

 

 

 

 

 

 

 

 

 

 

Regular equity program

 

 

11,172,627

 

 

 

 

 

$

25.76

 

 

 

6.2

 

 

$

78,764

 

Eidos Awards Exchange

 

 

1,014,175

 

 

 

 

 

$

14.18

 

 

 

4.3

 

 

$

13,734

 

Exchange Program

 

 

313,081

 

 

 

 

 

$

2.20

 

 

 

4.3

 

 

$

7,995

 

Granted

 

 

 

 

 

180,733

 

 

 

 

 

 

 

 

 

 

Regular equity program

 

 

180,733

 

 

 

 

 

$

38.59

 

 

 

 

 

 

 

Exercised

 

 

 

 

 

(473,820

)

 

 

 

 

 

 

 

 

 

Regular equity program

 

 

(376,191

)

 

 

 

 

$

23.08

 

 

 

 

 

 

 

Eidos Awards Exchange

 

 

(92,554

)

 

 

 

 

$

10.72

 

 

 

 

 

 

 

Exchange Program

 

 

(5,075

)

 

 

 

 

$

1.39

 

 

 

 

 

 

 

Cancelled

 

 

 

 

 

(7,183

)

 

 

 

 

 

 

 

 

 

Regular equity program

 

 

(7,183

)

 

 

 

 

$

36.37

 

 

 

 

 

 

 

Outstanding as of June 30, 2025

 

 

 

 

 

12,199,613

 

 

 

 

 

 

 

 

 

 

Regular equity program

 

 

10,969,986

 

 

 

 

 

$

26.06

 

 

 

5.8

 

 

$

205,275

 

Eidos Awards Exchange

 

 

921,621

 

 

 

 

 

$

14.53

 

 

 

3.8

 

 

$

26,408

 

Exchange Program

 

 

308,006

 

 

 

 

 

$

2.22

 

 

 

3.8

 

 

$

12,616

 

Exercisable as of June 30, 2025

 

 

 

 

 

10,912,545

 

 

 

 

 

 

 

 

 

 

Regular equity program

 

 

9,685,338

 

 

 

 

 

$

26.41

 

 

 

5.5

 

 

$

179,865

 

Eidos Awards Exchange

 

 

921,621

 

 

 

 

 

$

14.53

 

 

 

3.8

 

 

$

26,408

 

Exchange Program

 

 

305,586

 

 

 

 

 

$

2.21

 

 

 

3.8

 

 

$

12,519

 
Summary of Restricted Stock Award Activity

The following table summarizes BridgeBio’s RSU activity under the Plans for the six months ended June 30, 2025:

 

 

 

Unvested
Shares of
RSUs
Outstanding

 

 

Weighted-
Average
Grant Date
Fair Value

 

Balance as of December 31, 2024

 

 

10,272,798

 

 

$

21.91

 

Granted

 

 

4,111,660

 

 

$

33.95

 

Vested

 

 

(1,940,507

)

 

$

22.33

 

Cancelled

 

 

(591,178

)

 

$

21.08

 

Balance as of June 30, 2025

 

 

11,852,773

 

 

$

26.06

 
2019 Employee Stock Purchase Plan  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Schedule of Assumptions Used to Determine Fair Value of Stock Purchase Rights

We used the Black-Scholes model to estimate the fair value of stock options and stock purchase rights under the ESPP. For the six months ended June 30, 2025, we used the following weighted-average assumptions in the Black-Scholes calculations:

 

 

 

Stock Options

 

 

ESPP

 

Expected term (in years)

 

 

6.0

 

 

 

0.5

 

Expected volatility

 

94.0% - 94.7%

 

 

52.0% - 60.9%

 

Risk-free interest rate

 

4.1%

 

 

4.3% - 5.0%

 

Dividend yield

 

 

—

 

 

 

—

 

Weighted-average fair value of stock-based awards granted

 

$

30.15

 

 

$

11.88